Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization
Daniel R. Feikin, Laith J. Abu‐Raddad, Nick Andrews, et al.
Vaccine (2022) Vol. 40, Iss. 26, pp. 3516-3527
Open Access | Times Cited: 81

Showing 1-25 of 81 citing articles:

A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies
Srijan Chatterjee, Manojit Bhattacharya, Sagnik Nag, et al.
Viruses (2023) Vol. 15, Iss. 1, pp. 167-167
Open Access | Times Cited: 210
Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study
Jill M. Ferdinands, Suchitra Rao, Brian E. Dixon, et al.
BMJ (2022), pp. e072141-e072141
Open Access | Times Cited: 163
Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study
Julia Stowe, Nick Andrews, Freja Kirsebom, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 132
Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant
Melissa M. Higdon, Anurima Baidya, Karoline K Walter, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 8, pp. 1114-1116
Open Access | Times Cited: 130
Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
Hung Fu Tseng, Bradley K. Ackerson, Katia Bruxvoort, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 91
Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic
Rontgene Solante, Carlos Álvarez, Erlina Burhan, et al.
Expert Review of Vaccines (2022) Vol. 22, Iss. 1, pp. 1-16
Open Access | Times Cited: 43
Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period — IVY Network, 19 U.S. States, February 1, 2022–January 31, 2023
Jennifer DeCuir, Diya Surie, Yuwei Zhu, et al.
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 17, pp. 463-468
Open Access | Times Cited: 32
Covid-19 Surveillance Testing and Resident Outcomes in Nursing Homes
Brian E. McGarry, Ashvin Gandhi, Michael L. Barnett
New England Journal of Medicine (2023) Vol. 388, Iss. 12, pp. 1101-1110
Open Access | Times Cited: 31
Estimation of Vaccine Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron
Yuchen Wei, Katherine Min Jia, Shi Zhao, et al.
JAMA Network Open (2023) Vol. 6, Iss. 2, pp. e2254777-e2254777
Open Access | Times Cited: 29
Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization
Daniel R. Feikin, Melissa M. Higdon, Nick Andrews, et al.
Vaccine (2023) Vol. 41, Iss. 14, pp. 2329-2338
Open Access | Times Cited: 29
Informing the pandemic response: the role of the WHO’s COVID-19 Weekly Epidemiological Update
Juniorcaius Ikejezie, Alessandro Miglietta, Ingrid Hammermeister Nezu, et al.
BMJ Global Health (2024) Vol. 9, Iss. 4, pp. e014466-e014466
Open Access | Times Cited: 11
Clinical characteristics of the Omicron variant - results from a Nationwide Symptoms Survey in the Faroe Islands
Maria Skaalum Petersen, Sunnvør í Kongsstovu, Eina H. Eliasen, et al.
International Journal of Infectious Diseases (2022) Vol. 122, pp. 636-643
Open Access | Times Cited: 38
COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022
Limor Kliker, Neta S. Zuckerman, Nofar Atari, et al.
Eurosurveillance (2022) Vol. 27, Iss. 30
Open Access | Times Cited: 32
Effectiveness of COVID-19 vaccination against COVID-19 specific and all-cause mortality in older Australians: a population based study
Bette Liu, Sandrine Stepien, Timothy Dobbins, et al.
The Lancet Regional Health - Western Pacific (2023) Vol. 40, pp. 100928-100928
Open Access | Times Cited: 22
Synthetic Methodologies and Therapeutic Potential of Indole-3-Carbinol (I3C) and Its Derivatives
Federica Centofanti, Alessandro Buono, Michele Verboni, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 2, pp. 240-240
Open Access | Times Cited: 21
Household transmission of SARS‐CoV‐2 during the Omicron wave in Shanghai, China: A case‐ascertained study
Zhongqiu Wei, Wenjie Ma, Zhong Lin Wang, et al.
Influenza and Other Respiratory Viruses (2023) Vol. 17, Iss. 2
Open Access | Times Cited: 19
Vaccines Alone Cannot Slow the Evolution of SARS-CoV-2
Debra Van Egeren, Madison Stoddard, Laura F. White, et al.
Vaccines (2023) Vol. 11, Iss. 4, pp. 853-853
Open Access | Times Cited: 18
Reported effectiveness of COVID-19 monovalent booster vaccines and hybrid immunity against mild and severe Omicron disease in adults: A systematic review and meta-regression analysis
Joshua Nealon, Yonatan M. Mefsin, Martina McMenamin, et al.
Vaccine X (2024) Vol. 17, pp. 100451-100451
Open Access | Times Cited: 8
Relative effectiveness of COVID-19 vaccination with 3 compared to 2 doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian population with low prior rates of SARS-CoV-2 infection
Bette Liu, Heather F. Gidding, Sandrine Stepien, et al.
Vaccine (2022) Vol. 40, Iss. 43, pp. 6288-6294
Open Access | Times Cited: 25
Clinical Epidemiology and Risk Factors for Critical Outcomes Among Vaccinated and Unvaccinated Adults Hospitalized With COVID-19—VISION Network, 10 States, June 2021–March 2023
Eric P. Griggs, Patrick K. Mitchell, Victoria Lazariu, et al.
Clinical Infectious Diseases (2023) Vol. 78, Iss. 2, pp. 338-348
Open Access | Times Cited: 16
Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar
Ahmed Zaqout, Muna Almaslamani, Hiam Chemaitelly, et al.
International Journal of Infectious Diseases (2022) Vol. 124, pp. 96-103
Open Access | Times Cited: 21
COVID-19 vaccines versus pediatric hospitalization
Jaime S. Rosa Duque, Daniel Leung, Ka Man Yip, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 2, pp. 100936-100936
Open Access | Times Cited: 13
Who Is at Higher Risk of SARS-CoV-2 Reinfection? Results from a Northern Region of Italy
Maria Francesca Piazza, Daniela Amicizia, Francesca Marchini, et al.
Vaccines (2022) Vol. 10, Iss. 11, pp. 1885-1885
Open Access | Times Cited: 17
Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines
Moe H. Kyaw, Júlia Spinardi, Ling Zhang, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 11
The post-COVID-19 population has a high prevalence of cross-reactive antibodies to spikes from all Orthocoronavirinae genera
Gagandeep Singh, Anass Abbad, Giulio Kleiner, et al.
mBio (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top